Board of Directors
Director Election Procedures
All directors are elected under a candidate nomination system in accordance with the Company’s Procedures for Election of Directors. The professional qualifications, shareholding and concurrent position restrictions, independence requirements, nomination and election procedures, and other matters applicable to independent directors are handled in accordance with the relevant regulations of the securities regulatory authorities.
The independent director candidates for the current term were nominated in accordance with the above requirements, reviewed and approved by the Board of Directors, and submitted to the shareholders’ meeting for election from the list of candidates.
Board of Directors
At the 2024 Annual General Meeting of Shareholders held on June 28, 2024, the Company elected its 5th Board of Directors, including independent directors, for a three-year term from June 28, 2024 to June 27, 2027.
The 5th Board consists of nine directors, including three independent directors. On May 29, 2026, Diamond BioFund Inc., a corporate shareholder represented on the Board, appointed Mr. Kung-Ming Lu and Mr. Ching-Hung Lu as its representative directors. Mr. Kung-Ming Lu was subsequently elected Vice Chairman of the Board.
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
- 臺北醫學大學暨附屬機構體系總顧問
- 臺北醫學大學細胞治療與再生醫學研究中心主任
- 財團法人青杏醫學文教基金會董事長
- 財團法人王民寧先生紀念基金會董事
- 財團法人台大景福基金會董事
- 新光人壽保險股份有限公司獨立董事
- 財團法人台灣生技醫藥發展基金會榮譽董事
- 財團法人台灣醫界聯盟基金會董事
- 醫療財團法人徐元智先生醫藥基金會董事
- 臺灣生殖醫學會名譽理事
- 臺灣醫學會常務理事
- 臺灣人體生物資料庫學會榮譽理事
- 臺北醫學大學醫學院講座教授
- 臺灣大學醫學院婦產科名譽教授
- 臺灣大學醫學院附設醫院婦產部顧問醫師
- 元智大學董事
- 台北市立萬芳醫院婦產部主治醫師
- 醣基生醫股份有限公司科學諮詢委員
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
| 主要學歷 |
|
| 主要經歷 |
|
| 現職 |
|
2025 Board Operations
The Board of Directors meets at least once every quarter.
| 出席者 | 姓名 | 應出席次數 | 實際出席次數 | 出席率 | 備註 |
|---|---|---|---|---|---|
| 董事長本人 | 王嘉宗 | 6 | 6 | 100% | |
| 董事之法人代表人 | 林慧芬 | 6 | 6 | 100% | |
| 董事之法人代表人 | 吳友梅 | 4 | 4 | 100% | 2025.6.20卸任 2025.10.25接任 |
| 董事之法人代表人 | 高煜 | 2 | 2 | 100% | 2025.6.20接任 2025.10.23辭任 |
| 董事之法人代表人 | 鄭志慧 | 6 | 6 | 100% | |
| 董事之法人代表人 | 黃彥臻 | 6 | 5 | 83.33% | |
| 董事本人 | 李冬陽 | 6 | 6 | 100% | |
| 獨立董事本人 | 何弘能 | 6 | 6 | 100% | |
| 獨立董事本人 | 韓立群 | 6 | 6 | 100% | |
| 獨立董事本人 | 劉玄哲 | 6 | 6 | 100% |
Board Diversity
The selection of Board members is not restricted by gender, age, race, nationality, or other such factors, with particular emphasis placed on diversity in Board composition. The Board includes one director aged 70 or above, two directors aged 60–69, and six directors under the age of 60. Independent directors account for one-third of the Board. The Company intends to increase the proportion of female directors in the future.
To enhance corporate governance, the Board collectively possesses a diverse range of competencies, including but not limited to business judgment, accounting and financial analysis, management, crisis management, industry knowledge, international market perspectives, leadership, decision-making, and risk management knowledge and capabilities.
Board Diversity and Core Competencies：
| 多元核心項目 | 性別 | 營運判斷 | 會計及財務分析 | 經營管理 | 危機處理 | 產業知識 | 國際市場觀 | 領導能力 | 決策能力 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 姓名 | ||||||||||
| 董事長 | 王嘉宗 | 男 | V | V | V | V | V | V | V | V |
| 董事 | 李冬陽 | 男 | V | V | V | V | V | V | V | V |
| 董事 | 鑽石生技投資股份有限公司 代表人：黃彥臻 | 男 | V | - | V | V | V | V | V | V |
| 董事 | 鑽石生技投資股份有限公司 代表人：鄭志慧 | 女 | V | V | V | V | V | V | V | V |
| 董事 | 鑽石生技投資股份有限公司 代表人：吳友梅 | 女 | V | V | V | V | V | V | V | V |
| 董事 | 富邦金控創業投資股份有限公司 代表人：林慧芬 | 女 | V | V | V | V | V | V | V | V |
| 獨立董事 | 何弘能 | 男 | V | - | V | V | V | V | V | V |
| 獨立董事 | 韓立群 | 男 | V | V | V | - | V | V | V | V |
| 獨立董事 | 劉玄哲 | 男 | V | V | V | - | V | V | V | V |
Performance Evaluation
StemCyte is in the process of finalizing amendments to its “Board Performance Evaluation Policy,” which is expected to be approved by the Board in the near term. In accordance with the revised policy, the Company conducts annual performance evaluations of the Board of Directors and functional committees.
The Board performance evaluation covers the following five key aspects:
Participation in company operations
Enhancement of decision-making quality
Composition and structure of the Board
Director selection and ongoing education
Internal control
The performance evaluation of functional committees (including the Audit Committee and the Compensation Committee) covers the following five aspects:
Participation in company operations
Understanding of committee responsibilities
Enhancement of decision-making quality
Committee composition and member selection
Internal control
Evaluation Results
The 2025 Board performance evaluation was completed with an overall score of 4.92 out of 5.00. The results were reported to the Board of Directors on March 6, 2026.
The 2025 individual director performance evaluation was completed with an overall score of 4.95 out of 5.00. The results were reported to the Board of Directors on March 6, 2026.
The 2025 functional committee performance evaluations, covering the Audit Committee and Compensation Committee, were completed with scores of 4.50 and 4.50 out of 5.00, respectively. The results were reported to the Board of Directors on March 6, 2026.
The 2025 self-assessments of the Board of Directors, Audit Committee, and Compensation Committee all received an “Excellent” rating, indicating that the overall operations of the Board and its functional committees were satisfactory.